ReviewFrontiers in immunology2026
Gut microbiota-derived metabolites in gastrointestinal cancer: immunomodulatory mechanisms via the tryptophan-AhR axis and translational perspectives.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota contributes to host physiological homeostasis through the production of diverse bioactive metabolites that orchestrate immune responses, maintain intestinal barrier integrity, and regulate metabolic signaling. Increasing evidence indicates that these microbiota-derived metabolites act as critical mediators linking microbial composition to gastrointestinal tumorigenesis. Among them, short-chain fatty acids (SCFAs), bile acids, and amino acid-derived metabolites-particularly tryptophan metabolites-have been most extensively studied. These metabolites influence tumor initiation and progression via multiple mechanisms, including modulation of inflammatory responses, epigenetic remodeling, control of cell proliferation and apoptosis, and reprogramming of the tumor microenvironment (TME). This review provides a systematic overview of the sources, biological functions, and mechanistic roles of major gut microbial metabolites in gastrointestinal cancer. We emphasize three interconnected regulatory axes: inflammation-immunity modulation, intestinal barrier homeostasis, and metabolism-epigenetic reprogramming, while highlighting the tryptophan-aryl hydrocarbon receptor (AhR) axis as a central immunoregulatory hub. SCFAs generally exert protective effects by reinforcing epithelial barrier function and supporting anti-tumor immunity, whereas bile acids display context-dependent duality, with secondary bile acids being closely associated with chronic inflammation, DNA damage, and colorectal cancer progression. Tryptophan metabolites primarily shape mucosal immunity and tumor immune escape through activation of AhR signaling. Despite substantial progress, important challenges remain, including incomplete causal understanding, marked inter-individual variability, and limited clinical translation. Future studies integrating multi-omics approaches, single-cell and spatial technologies, and prospective clinical validation will be essential for defining key metabolite networks and advancing metabolite-based biomarkers and precision therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.